Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

Can NFκB2 be used as a biomarker for proteasome inhibitor response in MM?

Leon Bernal-Mizrachi • 14 Sep 2019
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide

Leon Bernal-Mizrachi, MD, of Emory University, Atlanta, GA, discusses a study aiming to characterize whether NFκB2 gene rearrangement can predict response to ixazomib in multiple myeloma. This Phase II trial tests ixazomib and dexamethasone vs. ixazomib, dexamethasone and lenalidomide, randomized with NFκB2 rearrangement (NCT02765854). This interview took place at the international myeloma workshop (IMW) 2019, in Boston, MA.

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals